Background: The t(12;21)(p13;q22), which fuses ETV6 and RUNX1 genes, is the most common genetic 32 abnormality in children with B-cell precursor acute lymphoblastic leukaemia. The implication of the 33 fusion protein in leukaemogenesis seems to be clear. However, its role in the maintenance of the disease 34 continues to be controversial. Aim: To eliminate the expression of the ETV6/RUNX1 fusion gene, in order 35 to elucidate the effect in the leukaemic cells. Methods: Generation of an in vitro ETV6/RUNX1 knock out 36 model using the genetic modification system CRISPR/Cas9. Functional studies and generation of edited-37 cell xenograft model were carried out. Results: For the first time, the expression of ETV6/RUNX1 fusion 38 gene was completely eliminated, thus generating a powerful model on which to study the role of the 39 fusion gene in leukaemic cells. ETV6/RUNX1 inactivation caused the deregulation of cellular processes 40 that could be participating in the maintenance of the leukaemic phenotype, such as differentiation and 41 lymphoid activation, apoptosis, cell signaling and cell migration. Tumour cells showed higher levels of 42 apoptosis, lower proliferation rate and a greater sensitivity to PI3K inhibitors in vitro along as a decrease 43 in tumour growth in xenografts models after ETV6/RUNX1 fusion gene abrogation. Conclusions: 44 ETV6/RUNX1 fusion protein plays a fundamental role in the maintenance of the leukaemic phenotype, 45 thereby being making the fusion protein a potential therapeutic target. 46 47 BACKGROUND
48
The gene fusion between the transcription factors ETV6 (TEL) and RUNX1 (AML1) is generated by 49 t(12;21)(p13; q22), the most frequent chromosomal translocation in children with acute lymphoblastic 50 leukaemia (ALL). 1,2 Patients carrying this translocation are associated with a good prognosis and 51 excellent molecular response to treatment. However up to 20% of cases relapse. 3-7 Furthermore, the 52 response to treatment of some relapse cases is associated with resistance to treatments such as 53 glucocorticoids (GCs), 8 and these patients must be treated with stem cell transplantation. 9 54 ETV6/RUNX1 (E/R) protein is known to play a role in the development of B-ALL, but by itself it is not 55 able of initiating the disease. Postnatal genetic events are required for the development of clinically overt 56 leukaemia. These second events are usually mutations or deletions, such as the loss of wild type (WT) 57 allele of ETV6. 10 Recent studies suggest that E/R is responsible for the initiation of leukaemia and also 58 essential for disease progression and maintenance, through deregulation of different molecular pathways 59 that contribute to leukaemogenesis. E/R regulates phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway, which promotes proliferation, cell adhesion 61 and DNA damage response; STAT3 pathway involved in self-renewal and cell survival and MDM2/TP53 62 whose deregulation induces the inhibition of apoptosis and consequently cell survival. 11 Therefore, the 63 fusion protein could thus be intervening in relapse processes and in the lack of response to treatment.
64
However, the functional studies carried out by the silencing of E/R fusion gene expression, mediated by 65 siRNA and shRNA, reveal that there is still controversy about the role of the oncoprotein in the 66 maintenance of the leukaemic phenotype. Thus E/R silencing by siRNA neither induced cell cycle 67 arrest/apoptosis nor attenuated clonogenic potential of cells. Therefore the E/R fusion protein may be 68 dispensable for the survival of definitive leukaemic cells. 12 By contrast, other studies showed that E/R 69 expression was critical for the survival and propagation of the respective leukaemia cells in vitro and in 70 vivo. 13 These results arise some doubts about the implications of the fusion protein in tumour cells.
71
The implementation of new genetic editing strategies has allowed the development of functional studies 72 by generation of gene and gene fusion KO models, both in vitro and in vivo. 14 In this study, we 73 completely abrogated the expression of E/R fusion protein in REH ALL cell line using the CRISPR/Cas9 74 editing system and we studied the effects of genetic ablation of the fusion protein in cellular functions.
75
We also studied whether the suppression of E/R expression sensitize tumour cells to PI3K inhibitors.
76
Finally, we generated a xenograft mouse model to study the oncogenic potential of tumours cells after 77 E/R depletion. In summary, we provide evidence that fusion protein has a key role in the maintenance of 78 the leukaemic phenotype. 237 3). Some of these genes have been previously associated with ALL pathology and have also been shown 238 to be directly regulated by RUNX1 transcript factor 20 (Table 1) 
318
This tumour was significantly smaller than those generated from REH cells (mean mass: 40 mg 
389
Finally, we wanted to check if E/R abrogation also decreased the tumour potential of cells in vivo. For 390 that, a xenograft model was generated by injecting these cells into immunosuppressed mice, taking the 391 injection of REH cells or a control clone on the opposite flank as control. Mice injected with KO clone 392 cells did not generated tumours or generated smaller tumours than those generated by REH cells or 393 control clone. The higher rate of mitotic activity in REH and control tumours observed through the 394 histopathology analysis explains the greater growth of these tumours and reveals a greater tumoural 395 capacity of these cells carrying E/R fusion gen in vivo.
396
Together these data suggest that the E/R fusion gene has a key role in the maintenance of the leukaemic 397 phenotype. By eliminating E/R expression, the cells lost tumourigenic capacity, becoming more sensitive 398 to drugs and reducing their oncogenic capacity in vitro and in vivo. Therefore, although more studies are 399 needed to elucidate the mechanism of action of the fusion gene, this study demonstrates that it could be a 400 possible therapeutic target to design new drugs that prevent the correct expression of this protein. 
